Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

John P. DeVincenzo(University of Tennessee Health Science Center), Jeff Cehelsky(Alnylam Pharmaceuticals (United States)), Rene Alvarez(Alnylam Pharmaceuticals (United States)), Sayda M. Elbashir(Alnylam Pharmaceuticals (United States)), Jens Harborth(Alnylam Pharmaceuticals (United States)), Iva Toudjarska(Alnylam Pharmaceuticals (United States)), Lubomir V. Nechev(Alnylam Pharmaceuticals (United States)), Veeravagu Murugaiah(Alnylam Pharmaceuticals (United States)), A L van Vliet, Akshay Vaishnaw(Alnylam Pharmaceuticals (United States))
Antiviral Research
January 7, 2008
Cited by 246

Abstract


Related Papers

No related papers found

Powered by citation graph analysis